Advocates convened outside the U.S. Capitol on April 20, 2026, to discuss the implications of incarcerating individuals charged with marijuana-related offenses and to promote policy reforms. Concurrently, President Donald Trump signed an executive order focused on psychedelics, including psilocybin, MDMA, and ibogaine, aimed at expediting research and legitimizing an industry that has operated mainly in the underground sphere.
This executive order, issued four months after Trump’s attempt to reschedule cannabis, seeks to enhance clinical trials and "Right to Try" access for patients experiencing serious mental health issues, without altering the current drug scheduling. While the effort to reclassify cannabis remains stalled, industry stakeholders express concern about the slow pace of federal drug policy reviews, noting the intersection of scientific evaluation, legal standards, and political considerations.
Shawn Hauser from Vicente LLP, legal counsel for the National Compassionate Care Council, believes that the recent executive move could pave the way for cannabis reforms, emphasizing a shift towards a medical-first framework in drug policy discussions.
Concerns are also rising regarding the safety of ibogaine, especially related to its use in treating PTSD, depression, and addiction, amid ongoing cardiac risk evaluations. Experts stress that the next phase of implementation for the psychedelics executive order will be crucial, focusing on rigorous scientific standards and physician-led protocols.
While psychedelics are gaining prominence, they still lack a solid commercial market unlike the established cannabis industry, which has seen significant growth across numerous states. There’s optimism that momentum in both sectors can reinforce their legitimacy as viable plant-based alternative medicines.
Why this story matters:
- The executive order may shape the future of psychedelic research and drug policy.
Key takeaway:
- A medical-first approach is gaining support in U.S. drug policy discussions.
Opposing viewpoint:
- Critics highlight potential safety concerns surrounding psychedelics, particularly ibogaine’s risks.
